Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2013 2
2015 1
2016 1
2017 1
2020 3
2021 5
2022 6
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Ribas A, et al. Among authors: kelley h. Cancer Discov. 2021 Dec 1;11(12):2998-3007. doi: 10.1158/2159-8290.CD-21-0425. Cancer Discov. 2021. PMID: 34326162 Free PMC article. Clinical Trial.
Financial Socialization: A Decade in Review.
LeBaron AB, Kelley HH. LeBaron AB, et al. Among authors: kelley hh. J Fam Econ Issues. 2021;42(Suppl 1):195-206. doi: 10.1007/s10834-020-09736-2. Epub 2020 Nov 10. J Fam Econ Issues. 2021. PMID: 33192037 Free PMC article. Review.
Letter to the editor: Response to commentary by Julia Snethen.
Fairman JA, Kelley HJ, Ladden M. Fairman JA, et al. Among authors: kelley hj. Nurs Outlook. 2024 Jan-Feb;72(1):102100. doi: 10.1016/j.outlook.2023.102100. Epub 2023 Dec 12. Nurs Outlook. 2024. PMID: 38092605 No abstract available.
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.
Negrao MV, Papadimitrakopoulou VA, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker GV, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu J. Negrao MV, et al. Among authors: kelley h. JTO Clin Res Rep. 2022 Oct 26;4(3):100423. doi: 10.1016/j.jtocrr.2022.100423. eCollection 2023 Mar. JTO Clin Res Rep. 2022. PMID: 36925644 Free PMC article.
23 results